Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHER: Tailored Dose-Dense vs Standard Chemotherapy in High-Risk Breast Cancer
NCT00798070Phase 3Active, not recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2007
- Primary completion
- Apr 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
A Phase 3 trial of epirubicin, cyclophosphamide, docetaxel in breast cancer, sponsored by Karolinska University Hospital. Started Feb 2007; status: active, not recruiting.
02
Drugs
epirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00798070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798070.